Thomas Schurpf
Overview
Explore the profile of Thomas Schurpf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jackson J, Frederick C Streich Jr , Pal A, Coricor G, Boston C, Brueckner C, et al.
Sci Signal
. 2024 Jul;
17(844):eadn6052.
PMID: 38980922
Inhibitors of the transforming growth factor-β (TGF-β) pathway are potentially promising antifibrotic therapies, but nonselective simultaneous inhibition of all three TGF-β homologs has safety liabilities. TGF-β1 is noncovalently bound to...
2.
Heiser C, Simmons A, Revetta F, McKinley E, Ramirez-Solano M, Wang J, et al.
Cell
. 2023 Dec;
186(25):5620-5637.e16.
PMID: 38065082
Colorectal cancer exhibits dynamic cellular and genetic heterogeneity during progression from precursor lesions toward malignancy. Analysis of spatial multi-omic data from 31 human colorectal specimens enabled phylogeographic mapping of tumor...
3.
Liu J, Chiang H, Xiong W, Laurent V, Griffiths S, Dulfer J, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37328286
Background: Immune exclusion (IE) where tumors deter the infiltration of immune cells into the tumor microenvironment has emerged as a key mechanism underlying immunotherapy resistance. We recently reported a novel...
4.
Welsh B, Faucette R, Bilic S, Martin C, Schurpf T, Chen D, et al.
Int J Toxicol
. 2021 Mar;
40(3):226-241.
PMID: 33739172
Checkpoint inhibitors offer a promising immunotherapy strategy for cancer treatment; however, due to primary or acquired resistance, many patients do not achieve lasting clinical responses. Recently, the transforming growth factor-β...
5.
Martin C, Datta A, Littlefield C, Kalra A, Chapron C, Wawersik S, et al.
Sci Transl Med
. 2020 Mar;
12(536).
PMID: 32213632
Despite breakthroughs achieved with cancer checkpoint blockade therapy (CBT), many patients do not respond to anti-programmed cell death-1 (PD-1) due to primary or acquired resistance. Human tumor profiling and preclinical...
6.
Yu Y, Schurpf T, Springer T
J Biol Chem
. 2013 Sep;
288(45):32314-32325.
PMID: 24047894
Natalizumab antibody to α4-integrins is used in therapy of multiple sclerosis and Crohn's disease. A crystal structure of the Fab bound to an α4 integrin β-propeller and thigh domain fragment...
7.
Lu C, Mi L, Schurpf T, Walz T, Springer T
J Biol Chem
. 2012 Sep;
287(45):38244-53.
PMID: 22988250
We study a mechanism by which dimerization of the EGF receptor (EGFR) cytoplasmic domain is transmitted to the ectodomain. Therapeutic and other small molecule antagonists to the kinase domain that...
8.
Schurpf T, Chen Q, Liu J, Wang R, Springer T, Wang J
FASEB J
. 2012 May;
26(8):3412-20.
PMID: 22601780
Developmental endothelial cell locus-1 (Del-1) glycoprotein is secreted by endothelial cells and a subset of macrophages. Del-1 plays a regulatory role in vascular remodeling and functions in innate immunity through...
9.
Weitz-Schmidt G, Schurpf T, Springer T
J Biol Chem
. 2011 Oct;
286(49):42115-42122.
PMID: 21965670
The activation of α/β heterodimeric integrins is the result of highly coordinated rearrangements within both subunits. The molecular interactions between the two subunits, however, remain to be characterized. In this...
10.
Schurpf T, Springer T
EMBO J
. 2011 Sep;
30(23):4712-27.
PMID: 21946563
Lymphocyte activation triggers adhesiveness of lymphocyte function-associated antigen-1 (LFA-1; integrin α(L)β(2)) for intercellular adhesion molecules (ICAMs) on endothelia or antigen-presenting cells. Whether the activation signal, after transmission through multiple domains...